What is Day One Biopharmaceuticals Inc?
, a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.23B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 536,461 shares $423k | 0 |